首页 文献索引 SCI期刊 AI助手
首页 正文

Review Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Oct:154:113577. doi: 10.1016/j.biopha.2022.113577 Q17.52025

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)

从新的视角看待NAFLD：关注过氧化物酶体增殖激活受体α（PPARα）与法尼醇X受体（FXR）之间的串话作用 翻译改进

Shipeng Zhou  1, Huimin You  1, Shuting Qiu  1, Dawei Yu  1, Yan Bai  2, Jincan He  2, Hua Cao  3, Qishi Che  4, Jiao Guo  5, Zhengquan Su  6

作者单位 +展开

作者单位

  • 1 Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
  • 2 School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China.
  • 3 School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.
  • 4 Guangzhou Rainhome Pharm & Tech Co., Ltd, Science City, Guangzhou 510663, China.
  • 5 Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address: gyguoyz@163.com.
  • 6 Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address: suzhq@scnu.edu.cn.

    • DOI: 10.1016/j.biopha.2022.113577 PMID: 35988420

    摘要 Ai翻译

    Nonalcoholic fatty liver disease (NAFLD) is primarily caused by abnormal lipid metabolism and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic steatosis and nutritional and energy imbalances and is a chronic liver disease associated with a number of factors. Nuclear receptors play a key role in balancing energy and nutrient metabolism, and the peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR) regulate lipid metabolism genes, controlling hepatocyte lipid utilization and regulating bile acid (BA) synthesis and transport. They play an important role in lipid metabolism and BA homeostasis. At present, PPARα and FXR are the most promising targets for the treatment of NAFLD among nuclear receptors. This review focuses on the crosstalk mechanisms and transcriptional regulation of PPARα and FXR in the pathogenesis of NAFLD and summarizes PPARα and FXR drugs in clinical trials, laying a theoretical foundation for the targeted treatment of NAFLD and the development of novel therapeutic strategies.

    Keywords: Farnesoid X receptor; Nonalcoholic fatty liver disease; Peroxisome proliferator-activated receptor alpha; Targeted therapy.

    Keywords：farnesoid x receptor

    关键词：法尼醇x受体; 非酒精性脂肪肝病

    Copyright © Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Biomedicine & pharmacotherapy

    缩写：BIOMED PHARMACOTHER

    ISSN：0753-3322

    e-ISSN：1950-6007

    IF/分区：7.5/Q1

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)